Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage

Shaojiang Tian1, Guohua Ding, Ruhan Jia

  • 1Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.

Insights

Osteopontin (OPN) drives early macrophage infiltration, while macrophage colony-stimulating factor (M-CSF) regulates later accumulation in kidney disease. Atorvastatin reduces inflammation and fibrosis by downregulating OPN and M-CSF.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Tubulointerstitial macrophage accumulation is key in kidney disease progression.
  • Understanding the roles of infiltration and proliferation is crucial.
  • Atorvastatin's protective mechanisms require further elucidation.

Purpose of the Study:

  • To investigate the temporal roles of macrophage infiltration and proliferation in tubulointerstitial inflammation and fibrosis.
  • To evaluate the renoprotective mechanisms of atorvastatin in unilateral ureteral obstruction (UUO) nephropathy.

Main Methods:

  • UUO rat model treated with atorvastatin or vehicle.
  • Assessed osteopontin (OPN) and M-CSF expression via RT-PCR and immunohistochemistry.
  • Quantified macrophage accumulation (ED1 staining) and tubulointerstitial fibrosis.

Main Results:

  • OPN expression correlated with early macrophage infiltration (day 3).
  • M-CSF expression correlated with later macrophage accumulation (day 10).
  • Atorvastatin treatment attenuated OPN and M-CSF, reducing macrophage infiltration and fibrosis.

Conclusions:

  • OPN may drive early macrophage infiltration, while M-CSF regulates later accumulation in UUO nephropathy.
  • Atorvastatin's renoprotective effects are linked to downregulating OPN and M-CSF.
  • Targeting these factors may offer therapeutic strategies for kidney disease.